Genentech

Using OCT with your diabetes patientsOCT is one of the best way to assess patients for the presence of diabetic macular edema (DME)
Why 2016 drug approvals fell
Why 2016 drug approvals fellWhile FDA approved far fewer new drugs in 2016 than 2015, the agency quickly approved novel and breakthrough therapies.
FDA approves expansion of Avastin in ovarian cancerFDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer.
Breast cancer biosimilar shows equivalency to brand
Breast cancer biosimilar shows equivalency to brandTwo new major studies on a biosimilar to trastuzumab (Herceptin, Genentech) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency.
10 highlights from AAO 2016
Lung cancer drug approvedSoon after FDA granted accelerated approval for atezolizumab (Tecentriq, Genentech) to treat bladder cancer, the agency okayed the drug to treat metastatic non-small cell lung cancer (NSCLC).
Importance of adherence and follow-up in patients with diabetic retinopathyA 37-year-old male came to my office for the first time in 2014 for a diabetes eye examination at the insistence of his primary-care provider (PCP).
Giant cell arteritis treatment expeditedThe US Food and Drug Administration (FDA) is expediting its review of a new potential treatment for giant cell arteritis, a rare inflammatory disease that can cause permanent vision loss, Roche has announced.
What anti-PD-L1 immunotherapy approval means for urologyUrologist Peter Black, MD, discusses the recent FDA approval of atezolizumab (TECENTRIQ) for the most common form of bladder cancer as well as a complementary diagnostic test.
Why new bladder cancer drug is novelFDA recently granted accelerated approval for atezolizumab (Tecentriq, Genentech), the first drug for bladder cancer that utilizes the body’s immune system. The drug will be available by early June.